Report Archive
All Research
Page 32 of 43 · 1027 reports
51/100
ServiceNow: A Value Investing Study
The leading enterprise workflow operating-system platform (post-split share price $102.25), with strong subscription stickiness and high cash-flow quality, yet on a conservative Owner Earnings basis that treats stock-based compensation as a real cost, the roughly 41x multiple still looks tight; ideal buy range $70-85. Rating Watch: an excellent business, but at today's price you are buying the expectation of continued excellence rather than an obviously undervalued asset.
49/100
Stryker In-Depth Value Investment Research
Stryker is a global medical device platform leader with deep moats in orthopaedics, the Mako robotics platform, and neurovascular products. Cash flow continues to strengthen, but at roughly 36.6x PE, valuation is tight and the ideal buy range is $185-230. Research rating Watch: a high-quality compounder that deserves long-term attention, but the current price leaves limited margin of safety.
47/100
Howmet Aerospace Deep Value Investment Research
Howmet Aerospace is a high-quality leader in aero-engine components and fastening systems, with a deep moat and steadily expanding margins. The core thesis is that the business is strong, but the current PE of about 59.5x already prices in years of high growth, smooth M&A integration, and sustained premium valuation, leaving too little margin of safety. Research rating Watch: an excellent aerospace compounder, but the ideal entry range is $90-125 rather than today's price.
49/100
Medtronic Long-Term Value Investment Analysis
Medtronic is a global medical-device leader with diversified exposure across cardiovascular, neuroscience, surgical, and diabetes franchises. Its cash flow is resilient, but the current PE of about 22x sits near the upper end of a neutral valuation range, leaving too little margin of safety; adding exposure would be more attractive after a pullback to $60-65. Research rating Hold: a durable compounder, but current pricing limits expected return.
35/100
51WORLD: A Deep Research Report
A scarce Hong Kong-listed name on the digital-twin and physical-AI theme, with 2025 revenue of RMB 348 million and a gross margin that fell from 51.1% to 30.0%; at roughly 100x P/S, the price already discounts the optimistic scenario. 51Aes remains the engine of the income statement while the 51Sim growth leg has yet to monetize, putting a fair buy range at HK$35 to HK$50. Rating Watch: the technology and the theme are both scarce, but the current price has already priced in the bull case and needs 51Sim ramp and margin repair to be confirmed by the financials.
35/100
51WORLD Long-Term Value Research Report
A scarce Hong Kong-listed digital-twin pure play that still lost RMB 186 million in 2025, runs negative operating cash flow, and saw gross margin fall from 51.1% to 30.0%; at the current HK$98.55 the stock trades at more than 100x P/S, which has already bought the most distant success in advance. Owner earnings remain negative and the fair buy band is HK$5–10. Rating Avoid: a good story with weak cash flow priced for a future that has not yet shown up in the financials.
40/100
ConocoPhillips: A Long-Term Owner's Perspective
A leading independent upstream oil and gas producer with 2.375 million BOE/day of production and 7.637 billion BOE of proved reserves, ConocoPhillips stands out for asset diversification and capital discipline. Rating: Watch — at $120.46 and 20.4x P/E, the stock already carries a high-quality premium with no clear margin of safety.
41/100
BAC: A Long-Term Owner Perspective Value Analysis
The second-largest U.S. commercial bank, with 2025 revenue of $113.1 billion and ROTCE of 14.22% on a solid platform. At the current price of $51.8 (about 1.34x book value / 1.80x tangible book value), it reads more as a 'good company at a fair price' than a bargain, with an ideal buy range of $40-45. Rating: Watch.
40/100
BDX: A Long-Term Business Owner's Investment Analysis
Following the Waters spin-off, New BD is more focused, with consumables making up over 90% of revenue and FY2026 adjusted EPS guidance of 12.52-12.72; but ROIC is only 4-5%, Debt/EBITDA sits at 4.28x, and the ideal buy range of $120-135 leaves an insufficient margin of safety.
42/100
Franklin Resources (BEN): A Deep Value Investing Study
A global asset-management platform with $1.68 trillion in AUM; traditional active management under pressure, plus the WAM controversy, plus sustained net long-term outflows, are narrowing its moat; at about $31.02 the stock sits near the middle of the neutral range, an ideal buy is $20-26, and the margin of safety is insufficient.
Brown-Forman: A Deep Value Investment Analysis
A global spirits leader built on the Jack Daniel's family, high gross margins, and a long dividend record. Net sales fell 5% in FY2025 and another 2% over the first nine months of FY2026, with management still guiding to a low-single-digit decline. At roughly $26 the stock sits in the middle of a $24–30 fair-value range, with an ideal buy zone of $20–23. Rating Watch: a high-quality compounder now priced closer to fair value than to a bargain, leaving little margin of safety.
44/100
BNY Mellon Long-Term Value Investment Research
A global financial-infrastructure leader: $59.4 trillion in AUC/A, 26.1% ROTCE, and 72% fee-based revenue. At the current $137.16, roughly 1.97x book value, the stock looks expensive, the ideal buy zone is $95-115, and the margin of safety is not ample. Rating: Watch.
49/100
BlackRock In-Depth Value Investment Research
BlackRock is the global leader in asset management, built around a 27.7% iShares ETF share and the dual platform of Aladdin and Preqin. The core thesis is a high-quality, scalable asset-management and investment-technology franchise, but at USD 1,073 the stock sits inside the optimistic valuation range at roughly 26.9x owner earnings, with an ideal buy price of USD 700 to 850. Research rating Watch: a durable compounder worth tracking, but the current price offers no obvious margin of safety.
43/100
Bristol-Myers Squibb: A Deep Value-Investing Study
A global large-cap pharma leader earning from patented, branded, and biologic drugs plus collaboration profit-sharing, with 2025 revenue of $48.19 billion, FCF of $12.85 billion, and a 4.24% dividend yield. At $59.46 the shares screen like a value stock and the ideal buy range is $45–52, but a patent cliff compounded by uncertain pipeline succession leaves the margin of safety too thin. Rating Watch: cheap for a reason, worth tracking rather than buying aggressively.
43/100
Broadridge Financial Solutions Deep-Dive Value Investing Analysis
A high-quality financial-infrastructure business. FY2025 free cash flow of $1.056 billion and a 97% recurring-revenue retention rate; but at $150.49 the stock already sits in the mid-to-upper part of the conservative $140-155 range / the low end of the fair range, so the margin of safety is not obvious.
Berkshire Hathaway: A Long-Term Owner's Perspective
A global diversified holding-company leader: 176 billion in insurance float, 397.4 billion in cash and short-term Treasuries, and 67 billion in net income. The capital-allocation record is excellent, but the Abel era is still unproven. At the current 486.38 dollars, with an ideal entry of 350 to 410 dollars, the margin of safety is not obvious. Rating Hold: a high-quality compounder priced fairly rather than cheaply.
44/100
Brown & Brown: A Deep-Dive Value Investment Analysis
A leading U.S. insurance brokerage platform selling property, casualty and employee-benefits products; 2025 revenue reached $5.9 billion (+22.5%) with free cash flow of $1.382 billion. The landmark Accession acquisition is still being integration-tested; the stock trades at $57.82 against an ideal buy range of $45–52. Quality is high but the margin of safety is limited, warranting a Cautious Buy.
46/100
Boston Scientific BSX Investment Research from a Long-Term Business Owner's Perspective
Boston Scientific is a global medtech leader with diversified cardiovascular and MedSurg platforms. 2025 revenue reached $20.074 billion, up 19.9%, with a 69% gross margin and $3.658 billion of FCF, but intensifying competition in electrophysiology and WATCHMAN, plus the large pending Penumbra acquisition, make the current $57.78 price look only fair to somewhat expensive versus an ideal buy range of $38 to $45. Research rating Watch: a high-quality business worth following closely, but not yet a clear margin-of-safety opportunity.
52/100
Blackstone: A Deep Value Investment Analysis
A global alternative asset management platform with $1.304 trillion in AUM and $539.7 billion in perpetual capital. At $118.51, the stock trades at roughly 19.5x economic-interest P/DE, with its quality premium already fully priced in. Rating Watch: a top-tier franchise worth owning, but only at a price that offers a real margin of safety, so wait for a better entry point as fundraising, exits, or valuation multiples reset.
35/100
BXP: A Deep Value Investment Analysis
A gateway-city Class A office REIT. At $60.29, the stock trades at 8.87x Price/FFO, 1.86x PB, and a 4.64% dividend yield. Asset quality is better than the industry average, but a demand re-rating plus heavy capex still pressure free cash flow. Rating Watch: a high-quality asset base in a headwind industry, priced fairly rather than cheaply; ideal buy price $40–48.
41/100
Citigroup Deep Value Investment Analysis
Global institutional banking's Services franchise is Citigroup's most valuable business. 2026 Q1 RoTCE rose to 13.1%, CET1 to 12.7%, and TBVPS to $99.01. At $125.09, the stock sits near the lower end of the $120-145 fair-value range — Rating Watch: regulatory remediation and a sustained 11-15% consolidated RoTCE remain unproven.
33/100
Conagra Brands: A Deep-Value Investment Analysis
A packaged-food company with mid-tier brands and a mid-tier moat. At $13.56, the stock trades at roughly 5x FY2025 P/FCF, and it is cheap for good reasons: high leverage, volume pressure, and a new CEO, John Brase, taking over in June. Rating Watch: a cheap cash-flow asset rather than a high-quality compounder, with an ideal buy range of $11 to $13.
41/100
Cardinal Health Deep Value Investment Analysis
A dominant U.S. pharmaceutical distribution oligopolist with cash flow that holds up well across the cycle, gaining extra credit for its pivot toward Specialty, MSO, and home care. But at $200.68, it trades at a trailing P/E of 31.9x and P/FCF of 25.6x — already in the middle of the $175-215 fair-value range, with an insufficient margin of safety.
44/100
Carrier Global: A Deep Value Investing Analysis
A global climate-control platform focused on HVAC and refrigeration after divesting fire and security. At $72.51 and a $61.17 billion market cap, the price already reflects the optimistic scenario, with Viessmann integration and data-center cooling as upside catalysts. Rated Watch, with a conservative value range of $36–45 and roughly 38–52% downside.